Analytical Data
-
基因名
FGFR1OP
- Application
-
别名
FGFR1OP；FGFR1OP；FOP;Centrosomal Protein 43
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O95684
-
表达区间
1-399aa
-
氨基酸序列
MAATAAAVVA EEDTELRDLL VQTLENSGVL NRIKAELRAA VFLALEEQEK VENKTPLVNE SLKKFLNTKD GRLVASLVAE FLQFFNLDFT LAVFQPETST LQGLEGRENL ARDLGIIEAE GTVGGPLLLE VIRRCQQKEK GPTTGEGALD LSDVHSPPKS PEGKTSAQTT PSKIPRYKGQ GKKKTSGQKA GDKKANDEAN QSDTSVSLSE PKSKSSLHLL SHETKIGSFL SNRTLDGKDK AGLCPDEDDM EGDSFFDDPI PKPEKTYGLR KEPRKQAGSL ASLSDAPPLK SGLSSLAGAP SLKDSESKRG NTVLKDLKLI SDKIGSLGLG TGEDDDYVDD FNSTSHRSEK SEISIGEEIE EDLSVEIDDI NTSDKLDDLT QDLTVSQLSD VADYLEDVA
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FGFR1OP (FGFR1 Oncogene Partner) is a protein that has garnered significant attention in the fields of cancer research and molecular biology due to its involvement in various cellular processes and oncogenic pathways. It was initially identified as a fusion partner for the FGFR1 gene in certain hematological malignancies, suggesting its role in tumorigenesis. FGFR1OP plays a crucial role in the regulation of cellular growth, differentiation, and survival, making it a potential target for therapeutic intervention. Research has shown that aberrant expression or mutation of FGFR1OP can lead to dysregulation of signaling pathways associated with cancer progression. Understanding the molecular mechanisms underlying FGFR1OP’s function and its interactions with other oncogenic proteins is essential for elucidating its role in neoplastic transformation. Furthermore, examining FGFR1OP’s involvement in signal transduction pathways may provide insights into new treatment options for cancers exhibiting FGFR1 alterations. Given the complexity of its interactions and the clinical implications of FGFR1OP dysregulation, ongoing studies are aimed at developing FGFR1OP-targeted therapies, with the hope of improving patient outcomes in specific cancer types.
